| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/16/2009 | CN101605798A Imidazothiazole derivatives |
| 12/16/2009 | CN101605797A Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| 12/16/2009 | CN101605794A Aza-benzofuranyl compounds and methods of use |
| 12/16/2009 | CN101605786A Imidazopyridine inhibitors of iap |
| 12/16/2009 | CN101605783A New N, N'- 2,4-dianilinopyrimidine derivatives, preparation thereof as drugs, pharmaceutical compositions essentially as ikk inhibitors |
| 12/16/2009 | CN101605782A 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular IKK inhibitors |
| 12/16/2009 | CN101605780A New 2, 4-dianilinopyrimidines, preparation thereof as drugs,pharmaceutical compositions and use thereof essentially as IKK inhibitors |
| 12/16/2009 | CN101605768A Chelating agent |
| 12/16/2009 | CN101605766A Pyrimidines derivatives and their use as kinase inhibitors |
| 12/16/2009 | CN101605763A Radioprotector compounds and related methods |
| 12/16/2009 | CN101605761A Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of HGFR gene |
| 12/16/2009 | CN101605553A Treatment of gastrointestinal diseases |
| 12/16/2009 | CN101605540A Methods of using MEK inhibitors |
| 12/16/2009 | CN101605535A Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| 12/16/2009 | CN101602811A Preparation method of cara eight sugar and application thereof |
| 12/16/2009 | CN101602808A Specific binding protein and application thereof |
| 12/16/2009 | CN101602791A Integrin receptor target lipidosome drug carrier, preparation method and application thereof |
| 12/16/2009 | CN101602778A CA-4P, preparation method and pharmaceutical composition thereof |
| 12/16/2009 | CN101602769A Podophyllum triazole derivants and application in preparing antiviral medicament and antitumor medicament |
| 12/16/2009 | CN101602768A Method for purifying sesamin and sesamolin |
| 12/16/2009 | CN101602756A Novel compunds, pharmaceutical compositions containing same, and methods of use for same |
| 12/16/2009 | CN101602754A Flavanone derivatives, preparation method and use thereof |
| 12/16/2009 | CN101602737A Benzenesulfonyl quinoxaline compound and preparation method and application thereof |
| 12/16/2009 | CN101602734A Method for preparing Erlotinib hydrochloride crystal form A |
| 12/16/2009 | CN101602731A Metalloproteinase inhibitors |
| 12/16/2009 | CN101602730A Substituted imidazole derivative |
| 12/16/2009 | CN101602728A N-substituted benzene ring 3,5-pyrazodione compounds, preparation method and application thereof |
| 12/16/2009 | CN101602707A Naphthaline lactam derivative and application thereof in propagation suppression of tumor cells |
| 12/16/2009 | CN101602659A Method for extracting xanthohumol in hop residue by supercritical CO2 technology |
| 12/16/2009 | CN101602657A Halogenated hydroxyl arone compounds, preparation method and use thereof |
| 12/16/2009 | CN101602653A Halogenated hydroxyl aromatic methane compounds, preparation method and use thereof |
| 12/16/2009 | CN101602652A Method for extracting resveratrol from moraceae plants |
| 12/16/2009 | CN101601856A Application of actinomycin compound actinomycin V in preparing drugs for anti liver cancer |
| 12/16/2009 | CN101601835A Tumor post-operation treating medicine and preparation method thereof |
| 12/16/2009 | CN101601812A Nutrient capable of strengthening human immunity and protecting cells of heat, brain, liver, kidney, stomach and intestine |
| 12/16/2009 | CN101601800A Chinese medicinal herb preparation for treating cancers and method for preparing same |
| 12/16/2009 | CN101601704A Application of radix sileris polysaccharose in preparing anti-liver-tumor medicament |
| 12/16/2009 | CN101601702A 抗老化剂 Anti-aging agents |
| 12/16/2009 | CN101601699A Kostelezkya virginica saponin preparation process and application |
| 12/16/2009 | CN101601695A Self-microemulsion nanometer composition of ganodenic acid extract and preparation method thereof |
| 12/16/2009 | CN101601668A Application of thiophene compound |
| 12/16/2009 | CN101601649A Ubenimex fat emulsion injection and preparation method thereof |
| 12/16/2009 | CN101601648A Sub-microemulsion used for intravenous injection of polyene yew alcohol phospholipid composite and preparation method thereof |
| 12/16/2009 | CN101601647A Riboflavine sodium phosphate composition injection and preparation method thereof |
| 12/16/2009 | CN100569945C Oligomeric compounds for the modulation of BCL-2 |
| 12/16/2009 | CN100569944C Production of polyketides and other natural products |
| 12/16/2009 | CN100569796C Immune modulating peptide |
| 12/16/2009 | CN100569793C Toad sterene compounds and application thereof in pharmaceutical preparation |
| 12/16/2009 | CN100569781C Dimeric flavone compound as well as preparation and application thereof in preparing anti-cancer medicine |
| 12/16/2009 | CN100569780C Fleshy glossy ganoderma lactone A, preparation process and use thereof |
| 12/16/2009 | CN100569776C Topoisomerase enzyme inhibitor, preparation method and application thereof |
| 12/16/2009 | CN100569773C Novel azaindole thiazolinones as anti-cancer agents |
| 12/16/2009 | CN100569764C Substituted benzamido methyl formate compound as well as preparation method and uses thereof |
| 12/16/2009 | CN100569754C Synthesis and application of serial ion liquid as candidate drug with anticancer activity |
| 12/16/2009 | CN100569753C A crystalline of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate a process for preparing the same |
| 12/16/2009 | CN100569740C N-OR amides compound, its preparing method and use |
| 12/16/2009 | CN100569739C Compound N-((2R,3S,E)-1,3-dihydroxy-17-methyloctadecyl-8-en-2-yl)acetamide |
| 12/16/2009 | CN100569298C DNA sequence of IER5-coded SiRNA, vector and application thereof |
| 12/16/2009 | CN100569296C Anticancer prior-medicine and method for preparing the same and use thereof |
| 12/16/2009 | CN100569289C Anticancer medicine composition of platinum compound and clorfarabine |
| 12/16/2009 | CN100569288C Solid tumor treating medicine composition |
| 12/16/2009 | CN100569281C Preparation and use of compositions for treating and preventing necrosis |
| 12/16/2009 | CN100569244C Self emulsified soft capsule of ginkgo leaf extract and its preparing method |
| 12/16/2009 | CN100569236C Application of N-substituted isatin derivates in preparing anti-tumor medicine |
| 12/16/2009 | CN100569233C Combination capable of preventing prostate gland cancer |
| 12/16/2009 | CN100569228C Fatty acid analogues for treatment of cancer |
| 12/16/2009 | CN100569219C Composition of oral medicine preparation and its preparing method |
| 12/16/2009 | CA2671223A1 Treatment of metastatic breast cancer |
| 12/15/2009 | US7634362 Computer programs for measuring activity and expression levels of cyclin dependent kinase 2 and HER2 genes; breast cancer diagnosis |
| 12/15/2009 | US7632951 Inhibitors of integrin ανβ6 |
| 12/15/2009 | US7632927 comprises an alpha-emitter (e.g. Bi-213) bound to the monoclonal antibody C595 by a chelating agent selected from DOTA, cDTPA, DTPA-CHX-A or TETA; anticarcinogenic agent particularly efficient for treatment of pancreatic and prostate cancer, as well as for breast and ovarian cancer |
| 12/15/2009 | US7632870 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
| 12/15/2009 | US7632858 For example, 1-(4-Cyano-2-ethyl-3-(trifluoromethyl)phenyl-1-carbamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid methyl ester; may be used in treatment of diseases or disorders associated with androgen receptor activity, such as maintenance of muscle strength and function in the elderly |
| 12/15/2009 | US7632855 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers |
| 12/15/2009 | US7632850 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS |
| 12/15/2009 | US7632839 Kinesin spindle protein (KSP) inhibitors, e.g., N-(3-amino-2-(R,S)-fluoropropyl)-N-[1-(3-benzyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidin-2-yl)-2-(R,S)-methylpropyl]-4-methylbenzamide; antiproliferative and -carcinogenic agents; side effects reduction |
| 12/15/2009 | US7632825 Methods of decreasing or preventing pain using spicamycin derivatives |
| 12/15/2009 | US7632813 Administering N-(3-{2-[3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl)cycloheptanecarboxamideas an inhibitor and a type of parathyroid hormone to treat and/orprevent bone metabolic diseases |
| 12/15/2009 | US7632808 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system |
| 12/15/2009 | US7632802 Reducing the risk of infection in a patient with lowered neutrophil count byadministering an immunostimulant S100 protein; immunosuppressed, chemotherapy-treatedpatients and those having bone marrow transplant; measurement of neutrophil bloodconcentrations; side effect reduction; cost efficiency |
| 12/15/2009 | US7632643 PCA3, PCA3 genes, and methods of use |
| 12/15/2009 | US7632514 a universal polypeptidic carrier for targeting molecules to a Gb3 receptor for the B-subunit of Shiga-Toxin expressing cells and its use for intracellular transport and processing of proteins, peptides, oligopeptides, glycoproteins, etc |
| 12/15/2009 | US7632504 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability |
| 12/15/2009 | US7632496 Administering to patient therapeutic dose of cytokine in combination with antibodies directed against tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN); method characterized in significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone |
| 12/15/2009 | CA2607940C Bir domain binding compounds |
| 12/15/2009 | CA2424884C Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| 12/15/2009 | CA2405747C Aminoflavone compounds, compositions, and methods of use thereof |
| 12/15/2009 | CA2403110C N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them |
| 12/15/2009 | CA2393437C Exo-s-mecamylamine formulation and use in treatment |
| 12/15/2009 | CA2347905C P53 antisense agent and method |
| 12/15/2009 | CA2345138C Polymer conjugates of interferon beta-1a and their uses |
| 12/15/2009 | CA2338000C Water-soluble 4-thio-maleimido derivatives and methods for their production |
| 12/15/2009 | CA2334189C Bridged indenopyrrolocarbazoles |
| 12/15/2009 | CA2333125C Alpha emitting constructs and uses thereof |
| 12/15/2009 | CA2276306C Loss of imprinting-based in vitro diagnostic method to determine the propensity to develop cancer |
| 12/15/2009 | CA2267175C Alpha-9 integrin antagonists and anti-inflammatory compositions thereof |
| 12/15/2009 | CA2255614C Dha-pharmaceutical agent conjugates |
| 12/10/2009 | WO2009149418A2 Novel compositions for the in vivo delivery of rnai agents |
| 12/10/2009 | WO2009149306A2 Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds |
| 12/10/2009 | WO2009149279A2 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |